Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...

Platform-specific achievement systems transformed an isolated gameplay preference into a visible, competitive subculture. What emerged wasn’t just a playstyle but an ecosystem of tracking tools, ...

At the core of every AI coding agent is a technology called a large language model (LLM), which is a type of neural network ...

When AI-assisted coding is 20% slower and almost half of it introduces Top 10-level threats, it’s time to make sure we're not ...

At its core, conservation is about behavior change. Yet few organizations have put in place the structure, standards, and ...

Creature collecting games are having a major moment right now, but one upcoming title feels especially promising in the wake ...

Liquid multivitamins provide several vitamins and minerals in an easy-to-take liquid form. Here’s how to pick the best ones, ...

The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...

Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic ...

Objective To examine whether a multicomponent commercial fitness app with very small (‘micro’) financial incentives (FI) ...

It wasn't exactly a surprise after months of leaks and speculation, but Nvidia CEO Jensen Huang (in perhaps his finest ...

Persistent recruitment delays, high dropout rates, and missed timelines continue to slow global clinical trials, while data show that sub-Saharan Africa offers a largely untapped opportunity with ...